Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Evaluation of Chemosensitivity for Low-risk Stage II/III Rectal Cancer
NCT03666442Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine in rectal cancer, sponsored by West China Hospital of Sichuan University. Started Jun 2018; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03666442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666442.